GlassScriptPhysician profile
Christopher Lee Paik
NPI 1548748957
$1,317.52
in general payments reported to CMS, 2019-2025
17 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.91 · 2021: $65.52 · 2022: $282 · 2023: $322 · 2024: $395 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $261.62 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $217.51 | 2019-2024 | Xarelto |
| Becton, Dickinson and Company | $177.50 | 2025 | Hemosphere |
| Phathom Pharmaceuticals, INC. | $124.82 | 2024 | Voquezna |
| Abbott Laboratories | $118.02 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $96.13 | 2021-2023 | |
| Glaxosmithkline, LLC. | $77.96 | 2023-2024 | Shingrix, Trelegy Ellipta |
| Kerecis Limited | $46.37 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Lilly USA, LLC | $45.11 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $35.47 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $24.59 | 2024 | Givlaari |
| Daiichi Sankyo INC. | $17.49 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.35 | 2022 | |
| Genzyme Corporation | $14.97 | 2022 | |
| Pfizer INC. | $14.43 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.13 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $14.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Paik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.